Section Arrow
Quote
TCRT.NASDAQ
- Alaunos Therapeutics Inc.
(Financial Status)
Quotes are at least 15-min delayed:2026/06/09 04:49 EDT
Pre Market
Last
 --
-- (--)
Bid
2
Ask
2.5
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 2
-0.28 (-12.28%)
Day High 
2.29 
Prev. Close
2.28 
1-M High
3.09 
Volume 
31.80K 
Bid
2
Ask
2.5
Day Low
2 
Open
2.29 
1-M Low
2.28 
Market Cap 
5.57M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.66 
20-SMA 2.58 
50-SMA 2.71 
52-W High 6.2 
52-W Low 1.67 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.12/-0.14
Enterprise Value
5.57M
Balance Sheet
Book Value Per Share
0.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.00K
Operating Revenue Per Share
1.20
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.5189+0.0031+0.60%-- 
Pre Market 0.486 -0.0329 -6.34%
ADTXAditxt Inc.0.0499-0.0122-19.65%-- 
Pre Market 0.0524 +0.0025 +5.01%
TNGXTango Therapeutics30.93+10.71+52.97%-- 
Pre Market 31.6997 +0.7697 +2.49%
GLMDGalmed Pharmaceuticals Ltd0.4693-0.2267-32.57%-- 
Pre Market 0.456 -0.0133 -2.83%
NRIXNurix Therapeutics15.64+1+6.83%-- 
Pre Market 15.06 -0.58 -3.71%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.